 PITTSBURGH, Sept. 01, 2021 GLOBE NEWSWIRE -- NeuBase Therapeutics, Inc. Nasdaq: NBSE NeuBase or the Company, a biotechnology platform company Drugging the GenomeTM to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 to 15. 